Back to discover

Protein / target

Granulocyte colony-stimulating factor receptor

Encoded byCSF3RQ99062Homo sapiensSwiss-Prot
UniProt: Q99062Ensembl: ENSG00000119535HGNC: HGNC:2439NCBI Gene: 1441
Clinically validated
Therapeutic maturity
9
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Antibody-tractable
Druggability
UniProt loc high conf

Protein at a glance

Biological role

Granulocyte colony-stimulating factor binding

Strongest disease association

Severe congenital neutropenia

Via encoding gene CSF3R · Genetic literature evidence · score 0.76

Therapeutic position

Established drug target

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation.

View complete UniProt function annotation

Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differentiation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface

Subcellular location

SecretedCell membrane
Domains and Gene Ontology detail (22)

Domains & features

Ig-like C2-typeFibronectin type-III 1Fibronectin type-III 2Fibronectin type-III 3Fibronectin type-III 4Fibronectin type-III 5

Gene Ontology

  • Cendocytic vesicle membrane
  • Cexternal side of plasma membrane
  • Cextracellular region
  • Clysosomal membrane
  • Cplasma membrane
  • Creceptor complex
  • Fcytokine binding
  • Fcytokine receptor activity
  • Fgranulocyte colony-stimulating factor binding
  • Fsignaling receptor activity
  • Pamelogenesis
  • Pcell adhesion

836 aa · 92 kDa · 4 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOImmune signallingGO
View supporting evidence

Cell proliferation & survival

  • ·positive regulation of cell population proliferation

Immune signalling

  • ·cytokine binding
  • ·cytokine receptor activity
  • ·cytokine-mediated signaling pathway

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

3 medicines · 3 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Neutropenia3 medicines
efbemalenograstim alfalipegfilgrastimpegfilgrastim
Infections1 medicine
pegfilgrastim
Broader indication categories (1)
Neoplasms3 medicines
efbemalenograstim alfalipegfilgrastimpegfilgrastim

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

9 medicines meet Open Targets' target-level approved-medicine definition; the 3 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

3

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

efbemalenograstim alfa
Narrow target profileApprovedAgonist

Granulocyte colony stimulating factor receptor agonist

Indicated for Neutropenia, Neoplasms

Direct interaction with this protein · Only this protein recorded as a target

lipegfilgrastim
Narrow target profileApprovedAgonist

Granulocyte colony stimulating factor receptor agonist

Indicated for Neutropenia, Neoplasms

Direct interaction with this protein · Only this protein recorded as a target

pegfilgrastim
Narrow target profileApprovedAgonist

Granulocyte colony stimulating factor receptor agonist

Indicated for Infections, Neutropenia, Neoplasms

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene CSF3R

Gene-level evidence surfaced through the gene CSF3Rthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Myelodysplastic syndrome
0.83Well supported

Clinical evidence dominant · Open Targets 0.64

Neoplasms
0.81Well supported

Clinical evidence dominant · Open Targets 0.63

Neutropenia
0.75Moderately supported

Clinical evidence dominant · Open Targets 0.60

Anemia, Aplastic
0.74Moderately supported

Clinical evidence dominant · Open Targets 0.56

Severe congenital neutropenia
0.73Moderately supported

Genetic evidence dominant · Open Targets 0.58

View evidence synthesis (5)
Myelodysplastic syndromeWell supported
0.83
agreement 0.72–0.94
Clinical58%Somatic mutation25%Animal model10%Literature7%

Open Targets aggregate 0.64 · 4 independent evidence families

NeoplasmsWell supported
0.81
agreement 0.69–0.93
Clinical69%Somatic mutation19%Literature13%

Open Targets aggregate 0.63 · 3 independent evidence families

NeutropeniaModerately supported
0.75
agreement 0.59–0.90
Clinical94%Literature6%

Open Targets aggregate 0.60 · 2 independent evidence families

Anemia, AplasticModerately supported
0.74
agreement 0.61–0.86
Clinical78%Animal model20%Literature2%

Open Targets aggregate 0.56 · 3 independent evidence families

Severe congenital neutropeniaModerately supported
0.73
agreement 0.59–0.87
Genetic93%Literature7%Genetic literaturedup

Open Targets aggregate 0.58 · 2 independent evidence families · 1 not counted as duplicate

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Myelodysplastic syndrome0.64
Neoplasms0.63
Neutropenia0.60
Severe congenital neutropenia0.58
Anemia, Aplastic0.56
Leukemia, Myeloid, Acute0.54
Infections0.53

Drug development

10 compounds recorded · 9 approved · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 3 drugs that target this protein in Forefront's canonical graph (3 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
BALUGRASTIMApproval
LENOGRASTIMApproval
LIPEGFILGRASTIMApproval
EFBEMALENOGRASTIM ALFAApproval
EFLAPEGRASTIMApproval
PEGFILGRASTIMApproval
FILGRASTIMApproval
ANUMIGILIMABPhase 2
PEGTEOGRASTIMApproval
REGRAMOSTIMApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Antibodies — Emerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination) — no clinical-stage drug of this modality recorded.

Other modalities — Strong

Approved Drug support this modality.

View underlying tractability evidence (5)
AB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

A Phase III Clinical Study of the Efficacy and Safety of Polyethylene Glycolized Human Granulocyte Stimulating Factor Injection (PEG-G-CSF) in Preventing Neutropenia After ChemotherapyPHASE3

ACTIVE_NOT_RECRUITING · via pegfilgrastim · NCT06711523

A Multicenter, Exploratory Clinical Study of Efbemalenograstim Alfa-vuxw Injection for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FNPHASE2

RECRUITING · via efbemalenograstim alfa · NCT07187908

ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label TrialPHASE3

RECRUITING · via pegfilgrastim · NCT06220032

A Prospective, Multicenter, Randomized Controlled Study of Etoposide, Cytarabine Combined With Pegfilgrastim vs. Cyclophosphamide Combined With G-CSF for Hematopoietic Stem Cell Mobilization in Newly Diagnosed Multiple Myeloma PatientsPHASE3

RECRUITING · via pegfilgrastim · NCT06520176

View all trials (26)
Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaPHASE3

RECRUITING · via pegfilgrastim · NCT06188676

A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to NephroureterectomyPHASE2/PHASE3

RECRUITING · via pegfilgrastim · NCT04628767

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaPHASE3

ACTIVE_NOT_RECRUITING · via pegfilgrastim · NCT04759586

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin LymphomaPHASE3

ACTIVE_NOT_RECRUITING · via pegfilgrastim · NCT03907488

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell TumorsPHASE3

ACTIVE_NOT_RECRUITING · via pegfilgrastim · NCT02375204

A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)PHASE3

ACTIVE_NOT_RECRUITING · via pegfilgrastim · NCT01933932

Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast CancerPHASE3

ACTIVE_NOT_RECRUITING · via pegfilgrastim · NCT00070564

A Phase III Randomized Study of EC Followed by Paclitaxel Versus FEC Followed by Paclitaxel, All Given Either Every 3 Weeks or 2 Weeks Supported by Pegfilgrastim, for Node Positive Breast Cancer PatientsPHASE3

ACTIVE_NOT_RECRUITING · via pegfilgrastim · NCT00433420

Phase II Study of Neoadjuvant RP2 in Combination With Preoperative Flot for Patients With Stage II or Higher, Non-metastatic Gastroesophageal AdenocarcinomaPHASE2

NOT_YET_RECRUITING · via pegfilgrastim · NCT07059611

Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies ConsortiumPHASE2

NOT_YET_RECRUITING · via pegfilgrastim · NCT07021989

Multicenter Phase II Study of Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell LymphomaPHASE2

NOT_YET_RECRUITING · via pegfilgrastim · NCT06594939

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) ± Rituximab + Recombinant Erwinia Asparaginase (JZP458; Rylaze®) for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Lymphoma/LeukemiaPHASE2

RECRUITING · via pegfilgrastim · NCT06738368

PHASE 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (GLOBOTRK)PHASE2

RECRUITING · via pegfilgrastim · NCT06528691

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory SarcomasPHASE1/PHASE2

RECRUITING · via pegfilgrastim · NCT06709495

Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6PHASE2

RECRUITING · via pegfilgrastim · NCT06690775

A Study of Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen With Risk Factors:A Single-Arm, Multicenter Clinical TrialPHASE2

RECRUITING · via efbemalenograstim alfa · NCT06251947

Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaPHASE2

RECRUITING · via pegfilgrastim · NCT05645718

NEO-adjuvant Chemo-Immunotherapy in Pancreatic CancerPHASE2

ACTIVE_NOT_RECRUITING · via pegfilgrastim · NCT06094140

A Phase 1b/2 Study of FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate CancerPHASE1/PHASE2

ACTIVE_NOT_RECRUITING · via pegfilgrastim · NCT05011188

A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell TumorPHASE2

RECRUITING · via pegfilgrastim · NCT04684368

A Phase II Study of Split-Dose R-CHOP in Older Adults With Diffuse Large B-cell LymphomaPHASE2

ACTIVE_NOT_RECRUITING · via pegfilgrastim · NCT03943901

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene AlterationsPHASE2

ACTIVE_NOT_RECRUITING · via pegfilgrastim · NCT03609216

A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AMLPHASE1/PHASE2

RECRUITING · via pegfilgrastim · NCT03214562

Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)PHASE2

RECRUITING · via pegfilgrastim · NCT03136146

A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung CancerPHASE2

ACTIVE_NOT_RECRUITING · via pegfilgrastim · NCT00334815

Ruxolitinib in Combination With Chemotherapy for Untreated Nodal T-Follicular Helper (TFH) Cell LymphomasPHASE1

RECRUITING · via pegfilgrastim · NCT07278856

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Label change2026-08-04

    Label change: PEGFILGRASTIM (BLA125031)

    fda · regulatory · fda · via pegfilgrastim

  2. CHMP positive opinion2026-07-24

    CHMP positive opinion: Cavoley (EMA)

    ema · regulatory · ema · via pegfilgrastim

  3. CHMP positive opinion2026-06-26

    CHMP positive opinion: Nylaspeg (EMA)

    ema · regulatory · ema · via pegfilgrastim

  4. Product recall2026-01-16

    Recall (Class I): PEGFILGRASTIM-CBQV

    fda · safety · fda · via pegfilgrastim

  5. Regulatory approval2025-08-18

    Approval: Vivlipeg (EMA)

    ema · regulatory · ema · via pegfilgrastim

  6. Supplemental approval2025-08-18

    Supplemental approval: PEGFILGRASTIM (BLA125031)

    fda · regulatory · fda · via pegfilgrastim

  7. Regulatory approval2025-03-28

    Approval: Dyrupeg (EMA)

    ema · regulatory · ema · via pegfilgrastim

  8. Regulatory approval2024-03-21

    Approval: Ryzneuta (EMA)

    ema · regulatory · ema · via efbemalenograstim alfa

  9. Regulatory approval2019-12-19

    Approval: Cegfila (previously Pegfilgrastim Mundipharma) (EMA)

    ema · regulatory · ema · via pegfilgrastim

  10. Regulatory approval2019-06-20

    Approval: Grasustek (EMA)

    ema · regulatory · ema · via pegfilgrastim

  11. Regulatory approval2018-11-20

    Approval: Fulphila (EMA)

    ema · regulatory · ema · via pegfilgrastim

  12. Regulatory approval2013-07-25

    Approval: Lonquex (EMA)

    ema · regulatory · ema · via lipegfilgrastim

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.